A Controlled Trial of Azathioprine in Behçet's Syndrome
- 1 February 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (5) , 281-285
- https://doi.org/10.1056/nejm199002013220501
Abstract
Cytotoxic agents have long been used in Behçet's syndrome, especially for eye involvement, but their effectiveness has been uncertain. We conducted a two-year randomized, placebo-controlled, double-blind trial of azathioprine (2.5 mg per kilogram of body weight per day) in Turkish men with Behçet's syndrome without eye disease (group 1; n = 25) or with eye disease (group 2; n = 48). Corticosteroid treatment remained available to all the patients.Keywords
This publication has 6 references indexed in Scilit:
- Neurologic Involvement in Behçet's SyndromeArchives of Neurology, 1989
- Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.Annals of the Rheumatic Diseases, 1988
- Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome.Annals of the Rheumatic Diseases, 1984
- Behçet disease (Behçet syndrome)Seminars in Arthritis and Rheumatism, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Les effets de l’Azathioprine («lmuran») dans la maladie de BehçetOphthalmologica, 1968